Vimarsana
Biggest News Aggregation in the World

Page 26 - Jeff Mclaughlin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeff Mclaughlin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeff Mclaughlin Today - Breaking & Trending Today

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: GSK/Vir collaborate on antibodies for influenza - Vimarsana News

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: GSK/Vir collaborate on antibodies for influenza

Investegate announcements from GlaxoSmithKline PLC, GSK/Vir collaborate on antibodies for influenza

CureVac AG: GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines - Vimarsana News

CureVac AG: GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines

CureVac AG: GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval GSK will also support manufacture of up to 100 million doses of CureVac's first generation COVID-19 vaccine CVnCoV in 2021 LONDON, UK / TUBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 3, 2021 / GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 ...

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: Final Results - Vimarsana News

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: Final Results

  GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER     Highlights Strong sales performance from key growth drivers in HIV, Respiratory, Oncology and Consumer Healthcare offset disruption from COVID-19 to adult vaccinations · Pharmaceuticals £17 billion -3% AER, -1% CER; new and specialty products £9.7 billion +11% AER, +12% CER · · · New ...

GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines - Vimarsana News

GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines

Press release content from Accesswire. The AP news staff was not involved in its creation. GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines February 3, 2021 GMT Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval GSK will also support manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine CVnCoV in 2021 LONDON, UK / TUBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / February 3, 2021 ...

Source: apnews.com
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment - Vimarsana News

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

(2) Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines...